Now available, the Rubicon Genomics webinar
Wednesday, December 3, 2014
Enrichment of cfDNA from Plasma for Next Generation Sequencing
Access the webinar recording here.
We hope you find the presentation educational and it stimulates your interest in the use of ThruPLEX® DNA-seq libraries for target enrichment.
Additional questions may be directed to:email@example.com
If you are interested in more information on the use of ThruPLEX® DNA-seq in cfDNA enrichment, click here to request a copy of our 2014 ASHG poster:
ThruPLEX® as a High Sensitivity Library Prep Tool forWhole Exome and Target Panel Sequencing
Cell-free (cf) DNA, found in plasma, is associated with various medical conditions and has been proposed as a non-invasive diagnostic tool. Recent publications* have provided proof of principle of valuable ways in which cfDNA can be used for non-invasive prenatal testing (NIPT) as well as cancer screening and management. Since the amount of cfDNA in plasma is limited, efficient protocols for creation of the NGS libraries and enrichment for coding sequences are critical.
In this webinar, we will demonstrate how to create high quality WES libraries from as little as sub-nanogram amounts of patient plasma DNA. We will describe:
- Purification of cfDNA from plasma
- Creation of libraries with ThruPLEX® DNA-seq kit from the purified cfDNA
- Protocols adapted for enriching coding sequences from ThruPLEX libraries
- Results obtained from sequencing the libraries
Dr. Jerome is an Applications Scientist at Rubicon Genomics where his primary responsibilities include protocol development for the use of ThruPLEX libraries for whole exome or target enrichment panel sequencing from low DNA input, such as cell-free DNA from plasma. Dr. Jerome completed his Ph.D at Michigan State University and did postdoctoral research in plant-microbe interactions at MSU in the Plant Research Laboratory where he was awarded an USDA AFRI NIFA Fellowship. Dr. Jerome was also a visiting researcher at the Wellcome Trust Sanger Institute training forin silicoNGS data analysis in the Pathogen Genomics Unit.
|J.P. Jerome, Ph.D.|
*Evaluation of exome sequencing to estimate tumor burden in plasma. Klevebring, D., Neiman, M., Sundling, S., Eriksson, L., Darai Ramqvist, E., Celebioglu, F., ... Lindberg, J. (2014). DOI: 10.1371/journal.pone.0104417
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Murtaza M, Dawson SJ, Tsui DW, Gale D, Forshew T, Piskorz AM, Parkinson C, Chin SF, Kingsbury Z, Wong AS, Marass F, Humphray S, Hadfield J, Bentley D,Chin TM, Brenton JD, Caldas C, Rosenfeld N. Nature. 2013 May 2;497(7447):108-12. DOI: 10.1038/nature12065. Epub 2013 Apr 7.
Noninvasive whole-genome sequencing of a human fetus. Kitzman JO, Snyder MW, Ventura M, Lewis AP, Qiu R, Simmons LE, Gammill HS, Rubens CE, Santillan DA, Murray JC, Tabor HK, Bamshad MJ, Eichler EE,Shendure J. Sci Transl Med. 2012 Jun 6;4(137):137ra76. DOI: 10.1126/scitranslmed.3004323